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a b s t r a c t
Aim: Percutaneous intervention is one of the treatment option for coronary artery disease.
Reinfarction and restenosis is one of the complication of the procedure. So this study was
conducted to assess plasma ﬁbrinogen levels pre- and post coronary stenting and its relation
with outcome.
Methods: After obtaining informed consent, venous blood samples were collected at three
timed points in relation to stenting – 24 h before, 24 h after and 72 h after stenting to assess
ﬁbrinogen levels. Patients were followed up for six months. Repeat revascularization,
myocardial infarction and symptomatic angina were considered as major adverse clinical
events.
Results: 57 patients who underwent successful stenting and followed up for six months up
were included in the study. Mean age was 53 years and 87.7% were males and 29.8% were
diabetics. Baseline plasma ﬁbrinogen level was signiﬁcantly high in patients who developed
repeat angina and myocardial infarction after the stenting [288.64  59.43 vs 393.75
 32.97 mg/dL, p = 0.003] and it remained high during serial assessment [322.74  63.92 vs
422.00  55.28 mg/dL, 326.23  65.81 vs 419.50  45.82 mg/dL, 0.008, 0.012 respectively].
Patients who developed adverse events denied any drug default.
Conclusion: We conclude that plasma ﬁbrinogen plays a signiﬁcant role in the development
of adverse events following stenting shown by high level of plasma ﬁbrinogen in patients
who developed adverse events.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.1. Background
Coronary heart disease [CHD] represents a major cause of
morbidity and mortality in the world today. The etiology of
CHD is multifactorial and is known to include diet, physical* Corresponding author. Tel.: +91 9791910174.
E-mail address: kavie2001@gmail.com (S. Kavitha).
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0019-4832/# 2015 Cardiological Society of India. Published by Elsevieinactivity, obesity, diabetes, hypertension, lipid levels etc. In
India, CHD is an epidemic and considered to be one of the
major causes of disease-burden and deaths.1
Percutaneous Intervention [PCI] has become the commonly
used treatment of symptomatic coronary artery disease withr B.V. All rights reserved.
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stent restenosis.2 Various factors are shown to affect the
outcome of stenting in a patient. Early elastic recoil, late vessel
remodeling, and neointimal proliferation have been proposed
as important contributors to the restenosis after coronary
angioplasty.3
Several studies have shown ﬁbrinogen as a major cardiac
risk factor. Fibrinogen affects platelet aggregation and blood
coagulation. Also ﬁbrinogen and its metabolites have direct
effects on the vascular wall.4,5
Otsuka and his colleagues [2002] studied the relation
between preprocedural ﬁbrinogen level and stent outcome
and occurrence of adverse cardiac events of patients
undergoing PCI. They concluded that preprocedural ﬁbrino-
gen level and stent length was an independent predictor of
coronary stent outcome.6 On the contrary, Pascalle and his
colleagues [2005] in their GENDER project concluded that
there is no association between preprocedural ﬁbrinogen
level and target vessel revascularization after coronary
stenting.7
Since conﬂicting results were shown by various studies
about baseline ﬁbrinogen levels and stent outcome, present
study was conducted with the idea to determine the relation
between preprocedural ﬁbrinogen levels and coronary stent
outcome and to study ﬁbrinogen level serially and coronary
stent outcome.2. Subjects and methods
2.1. Study subjects
70 cases undergoing elective PCI during the period 2009–2010
were enrolled in this study. Out of 70 cases, 62 cases had
successful stenting. Five cases were lost to follow up.
Patients were included if they were stented successfully for
stable or unstable angina and coronary heart disease with
normal levels of CK-2 activity in the 24 h preceding the
intervention. Exclusion criteria were Acute Coronary Syn-
drome [ACS], acute infections or previous PCI or Coronary
Artery Bypass Graft CABG] of the target vessel. The study was
approved by the institutional ethics committee. Written
informed consent was obtained from each subject before
the PCI procedure.
2.2. PCI procedure
Coronary stenting was done either using radial or femoral
route under a local anesthetic. Use of glycoprotein IIb/IIIa
receptor inhibitors and type of stent depended on the need of
the interventional cardiologist. Patency of the vessel was
assessed by angiography after the procedure was completed
and TIMI ﬂow 3 Normal blood ﬂow ﬁlling coronary bed
completely achieved.
All patients who underwent PCI received Clopidogrel
300 mg and aspirin 300 mg previous night and on the day of
surgery and continued to followup after the procedure.
Heparin 5000U and nitroglycerine were given during the
procedure. Another 2500U heparin was given if procedure
extends beyond one hour to maintain Activated Clotting Timeof 250–300 s every hour. Tiroﬁban was the GP IIb/IIIa blocker
used. Tiroﬁban was given to 25 patients out 57.
Atorvastatin, aspirin and clopidogrel were continued for
the patients for six months.
2.3. Lab analysis
2 ml of venous blood sample was collected in 3.8% citrate
added tubes from the patients 24 h prior to coronary stenting.
Two other venous blood samples were collected from the
patients after 24 h of stenting and after 72 h of stenting.
Plasma ﬁbrinogen was analyzed using Reagent kits from
Tulip Diagnostics, India.
2.4. Dyslipidemia
Hypercholesterolemia is having serum cholesterol of 200 mg/
dL and above. HDL less than 40 mg/dL was considered low
HDL. LDL level > 100 mg/dL was considered high.
2.5. Follow up and outcome measure
Patients were followed for six months. Outcomemeasure was
taken to be freedom from cardiac related adverse events for six
months. Cardiac related events included myocardial infarc-
tion, repeat revascularisation [either Percutaneous or Cardiac
surgery] and recurrence of symptomatic angina. Occurrences
of adverse events were collected from the patient's case
records.
2.6. Statistical analysis
All data are expressed as mean  standard deviation.
Repeatedmeasures ANOVA followed byMannWhitney test
was used to compare means of the parameters of serial
measurements.
p value of <0.05 was considered as signiﬁcant for all
statistical tests.
All analyses were performed with SPSS statistical software
[SPSS Inc., Chicago, Illinois].3. Results
3.1. Baseline patient characteristics
Mean age was 53 years and 87.7% were males and 29.8% were
diabetics.
3.2. Serial assessment of plasma ﬁbrinogen level
When compared to baseline level there is a signiﬁcant increase
in plasma ﬁbrinogen after 24 h of the procedure [p ≤ 0.001] and
after 72 h [p ≤ 0.001]. There is no signiﬁcant change when
plasma ﬁbrinogen levels were compared between the samples
collected after 24 h and 72 h of the procedure.
Changes in plasma ﬁbrinogen level during serial assess-
ment are given in Table 1.
Table 2 gives the details about the vessels involved and the
number of stents used.
Table 1 – Periprocedural changes in plasma fibrinogen
level [mg/dL].
Time Fibrinogen [mg/dL]
a 296  64
b 330  68*
c 333  69*
a – 24 h before stenting, b – 24 h after stenting, c – 72 h after
stenting * – Signiﬁcant on comparison with a p < 0.05 is signiﬁcant.
Table 2 – Vessel involved and number of stents used in
patients who underwent stenting.
S No. Characteristics Total n = 57
1 Vessel involved
LAD, n (%) 30 (53)
RCA, n (%) 6 (11)
LCx, n (%) 6 (11)
LAD/RCA, n (%) 7 (12)
LAD/LCx, n (%) 6 (11)
RCA/LCx, n (%) 2 (4)
2 No. of Stents
1, n (%) 45 (79)
2, n (%) 12 (21)
Table 4 – Serial measurement of plasma fibrinogen levels
in patients who developed and did not develop adverse
events.
Time Patients who did not
develop adverse events,
n = 53 [mg/dL]
Patients who
developed adverse
events, n = 4 [mg/dL]
p
a 288.64  59.43 393.75  32.97 0.003
b 322.74  63.92 422.00  55.28 0.008
c 326.23  65.81 419.50  45.82 0.012
a – 24 h before stenting, b – 24 h after stenting, c – 72 h after
stenting.
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During follow up for 6 months, four patients developed
adverse events. Two patients had acute myocardial infarction
and two patients had unstable angina. There was no drug
default among the patients.
Table 3 shows the baseline characteristics of patients who
developed and did not develop adverse events.
18 patients had hypercholesterolemia. 43 out of 57 patients
had low HDL. LDL was high in 44 patients out of 57.
[LDL > 100 mg/dL in 44/57, LDL > 130 mg/dL in 24/57,
LDL > 160 mg/dL in 7/57].Table 3 – Baseline characteristics of patients who devel-








events, n = 4
Age [yrs] 52.8 53.2
Sex [F:M] 6:47 1:3
Smoking, n [%] 24 [45] 0 [0]
Diabetes, n [%] 15 [28] 2 [50]
Hypertension, n [%] 19 [36] 0 [0]
Obesity, n [%] 15 [28] 1 [25]
Dyslipidemia, n [%]
Hypercholesterolemia 15 [28] 3 [75]
High LDL 44 [83] 3 [75]
Low HDL 40 [75] 3 [75]
Tiroﬁban use, n [%] 23 [43] 2 [50]
Type of stent
Bare metal stent, n [%] 35 [66] 2 [50]
Drug eluting stent, n [%] 18 [34] 2 [50]
Fibrinogen level [mg/dL] 288.64  59.43* 393.75  32.97*
*p = 0.003.Comparison of baseline characteristics like diabetes, hyper-
tension, obesity and dyslipidemia between patients who
patients who developed and did not develop adverse events
did not provide signiﬁcant results. No signiﬁcant difference in
incidence of adverse events with tiroﬁban use. The rise in
plasma ﬁbrinogen level after stenting is similar in both bare
metal and drug eluting stents, but no signiﬁcant difference
between the types of stents. No statistically signiﬁcant changes
in CK2 following stenting or its association with ﬁbrinogen.
The mean levels of plasma ﬁbrinogen at 24 h before
procedure is signiﬁcantly high in patients who developed
adverse events [393.75  32.97 mg/dL vs 288.64 59.43 mg/dL,
p = 0.003].
The plasma ﬁbrinogen levels of the 2 groups were
compared in Table 4.
Plasma ﬁbrinogen levels in patients who developed and did
not develop adverse events after 24 and 72 h of procedurewere
322.74  63.92 mg/dL vs 422.00  55.28 mg/dL and 326.23
 65.81 mg/dL vs 419.50  45.82 mg/dL [p = 0.008 and 0.012
respectively].
4. DiscussionFibrinogen is an acute phase reactant protein and a proin-
ﬂammatory marker which plays an important role in platelet
aggregation, increases plasma viscosity, causes the release of
vasoconstrictormediators and growth factors and also leads to
ﬁbrin deposits.7
In the present study, plasma ﬁbrinogen level was increased
following stenting and the level remained elevated at 72 h.
This may be due to disruption of the vascular wall by stenting
which may attract various inﬂammatory cells which may
result in cytokine production. This leads to increased produc-
tion of acute phase proteins including ﬁbrinogen.8
Plasma ﬁbrinogen level increased after stenting irrespec-
tive of type of stent used [both bare metal and drug eluting
stents], but no signiﬁcant difference between types of stents
indicating that the stenting procedure induced an inﬂamma-
tory response.
In the present study, patients who developed adverse
events during six month follow up had their baseline plasma
ﬁbrinogen level more than 350 mg/dL. Various studies has
shown that patients with baseline plasma ﬁbrinogen level
more than 350 mg/dL during follow up had more restenosis
and adverse events when compared to patients with plasma
ﬁbrinogen level below 350 mg/dL6,9
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due toneointimalproliferation.Themigrationandproliferation
of smooth muscle cells, induced by the production and release
of growth factors, cytokines and extracellularmatrix synthesis,
result in neointimal formation and eventually represents the
restenosis.3,10 Stent implantation induces a vascular inﬂam-
matory response which also contributes to restenosis.10
Increased ﬁbrinogen causes alterations in ﬁbrin clot
structure and this is shown to impair ﬁbrinolysis and increase
the risk of cardiovascular events following stent procedure
including stent thrombosis.
Fibrinogen may be considered a risk factor for restenosis
because ﬁbrin degradation products stimulate smooth muscle
cell outgrowth which is seen in neointimal proliferation
leading to restenosis.7,9 For example, ﬁbrinogen can promote
endothelial-cell migration and extracellular accumulation of
low-density lipoproteins. Fibrinogen can promote platelet
aggregation by interacting with GP IIb/IIIa receptors on the
platelet membrane. In addition, an elevated level of plasma
ﬁbrinogen increases blood viscosity,5 which causes impaired
microcirculatory ﬂow, endothelial shear-stress damage, and
predisposition to thrombosis.11
Recently Enright k et al studied measurement of ﬁbrinogen
and platelet reactivity with adverse events following PCI
procedure and showed that ﬁbrinogen measurements before
procedure adverse cardiac related events.12
In the present study, only incidence of adverse events
during sixmonth follow upwas assessed. Angiographic follow
up was not done and hence percentage of restenosis was not
determined. Two of the four patients who developed adverse
events following stenting were diabetic. Effect of uncontrolled
or poorly controlled diabetes on stent outcome is to be studied.
We conclude that there is an increased inﬂammation
following stenting and high baseline plasma ﬁbrinogen level
can be used to assess risk for development of adverse cardiac
events following PCI.
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